Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 32Thoracic 7Gynecologic 6Gastrointestinal 6Breast 6Dermatologic 2CNS 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Sarcoma 16Ovarian Neoplasms 8Hemangiosarcoma 7Endometrial Neoplasms 7Carcinosarcoma 7Breast Neoplasms 6Sarcoma, Kaposi 4Neoplasms 4Melanoma 4Lymphoma, Non-Hodgkin 4Central Nervous System Neoplasms 4Brain Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Medulloblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Gliosarcoma 3Glioma 3Glioblastoma 3Gastrointestinal Stromal Tumors 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3Cryosurgery 3Biopsy 3eribulin 2durvalumab 2balstilimab 2atezolizumab 2aflibercept 2Zoledronic Acid 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Letrozole 2Irinotecan 2Gene Expression Profiling 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Paclitaxel × Sarcoma × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡